Iris Pharma and RxGen Partner to Deliver Seamless and Superior Drug & Medical Devices Development Services in Ophthalmology Nice, France, and Hamden, CT, USA, April 19, 2012 – Iris Pharma, a leading ophthalmic preclinical and clinical contract research organization (CRO), and RxGen, a specialty preclinical CRO focused on the development and application of translational research models, ...
Therapeutic Development Through Innovative Research
RxGen & Miragen Secure SBIR Funding to Evaluate Role of microRNAs in Cardiac Disease
HAMDEN, Conn., and BOULDER, Colo., August 25, 2011 – RxGen, a specialty preclinical contract research organization, and miRagen Therapeutics, Inc., a preclinical-stage biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today the award of a Small Business Innovation Research (SBIR) grant by the National ...
RxGen Optimizes the CNV model of Wet-AMD in Nonhuman Primates
Hamden, CT --- March 21, 2011 --- RxGen, a specialty preclinical contract research organization, announced today that Experimental Eye Research has published results of efforts to optimize the laser-induced choroidal neovascularization (CNV) model in nonhuman primates, which is routinely employed to evaluate candidate compounds or drug delivery devices designed to treat wet-AMD. Despite widespread use of ...
AAALAC Accreditation Awarded to RxGen Research Facilities
Hamden, CT --- September 27, 2010 --- RxGen, a specialty preclinical contract research organization, announced today that its research facilities have received full accreditation from the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International. RxGen’s research facilities are housed at the St. Kiits Biomedical Research Foundation (SKBRF) in St. Kitts, West Indies, a ...
RxGen Validates African Green Monkey Model of Wet-AMD
HAMDEN, CT May 2, 2010 – RxGen scientists have completed the validation of the laser-induced CNV model of wet-AMD in the African green monkey, migrating a disease model previously validated in other non-human primates to a species that offers considerable advantages with respect to both availability and genomic and anatomic similarity to humans. RxGen is ...
RxGen Hosts Second Annual “microRNA in Human Disease” Meeting with Santaris Pharma
HAMDEN, CT March 15, 2010 – RxGen announces the successful conclusion of its second annual microRNA in Human Disease meeting, co-hosted and sponsored by Santaris Pharma and miRagen. This year’s meeting was designed to extend upon the unique format established in 2009, whereby leading principal investigators and postdoctoral scientists working in multiple aspects of microRNA ...
